Medicilon appeared at the 25th SAPA-NE Annual Conference

On June 3, 2023, the 25th annual conference of SAPA-NE (Sino-American Pharmaceutical Professionals Association–New England/Boston) was successfully held in Boston, MA. Dr. Chunlin Chen, CEO of Medicilon, Dr. Zhenrong Guo, Executive Vice President of Pharmaceutical Research, and the Medicilon US team attended the annual conference and had pleasant and in-depth exchanges with many guests and experts during the conference. With professional quality, confident demeanor, and exhibitions as a platform, Medicilon fully demonstrates and delivers the values of "focus on innovation, win-win collaboration, client first, and loving and dedication". During the conference, the Medicilon team conducted in-depth exchanges with a lot of pharmaceutical colleagues, and discussed about the industry situation and market prospects.

From left to right: Cindy Chen, Dr. Jun Li, Dr. Chunlin Chen, Dr. Zhenrong Guo, Dr. Yan Zhou

Dr. Chunlin Chen of Medicilon was invited to give a wonderful speech on "Medicilon Strategy & 20 Years Experience for Dual Filing of IND to US FDA & China NMPA along with IPO at STAR Market". Since its establishment in 2004, Medicilon has provided drug R&D services to more than 2,000 clients around the world during the 20-year milestone. More than 330 new drug and generic drug projects that have participated in the research and development have obtained IND approval. In the past 20 years, Medicilon has grown together with the partners around the world.

Based on Medicilon's nearly 20 years of experience in IND filing, Dr. Chen shared an in-depth analysis and case study.

The 25th SAPA-NE Annual Conference attracted many professionals from the biotechnology and pharmaceutical industries to attend. Through intensive exchanges and discussion, the participants had in-depth discussion with industry organizations on how to meet the transformation in this challenging situation. Participants exchanged views on new trends in the industry in terms of new drug R&D, AI pharmaceuticals, technological innovation, pharmaceutical investment, and regulatory oversight.

The audience listened to Dr. Chen's speech.

As the Diamond Sponsor of the 25th SAPA-NE Annual Conference, the dinner event was exclusively sponsored by Medicilon. The well-arranged drinks and snacks allowed participants to enjoy the opportunity to communicate with different professionals after a busy meeting. The buffet dinner drew a perfect end to the busy day of business negotiation.

Medicilon, as a professional biopharmaceutical preclinical R&D service CRO, provides global pharmaceutical companies and research institutions with a full range of one-stop new drug R&D services that meet both China and US filing standards. Through this exhibition, the influence of the Medicilon has been further enhanced internationally. In order to realize the vision of "providing a full range of preclinical research services for global pharmaceutical companies, research institutions and all scientific researchers, and promoting the process of new drug research", Medicilon will continue to deepen the overseas high-end market, explore the European and American markets, and accelerate the pace of internationalization.